Chronic Limb-Threatening Ischemia, Critical Limb Ischemia, Peripheral Arterial Disease
Conditions
Keywords
CLTI, PAD, CLI
Brief summary
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
Detailed description
The objective of this study is to provide additional information on the LimFlow System for creating an AV connection in the Below The Knee (BTK) vascular system using an endovascular, minimally invasive approach to arterialize the pedal veins for the treatment of chronic limb-threatening ischemia in subjects ineligible for conventional endovascular or surgical limb salvage procedures.
Interventions
DEVICELimFlow Stent Graft System
Creation of an arteriovenous fistula in the desired limb location
Sponsors
LimFlow, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
1. Subject must be ≥ 18 and ≤ 95 years of age 2. Clinical diagnosis of chronic limb-threatening ischemia, defined as any of the following clinical assessments: previous angiogram or hemodynamic evidence of severely diminished arterial inflow of the index limb (e.g., ABI ≤ 0.39, TP / TcPO2 \< 30 mm Hg) and 1. Rutherford Classification 5, ischemic ulceration or 2. Rutherford Classification 6, ischemic gangrene 3. Subject has been assessed by the Principal Investigator and determined that no conventional distal bypass, surgical or endovascular therapy for limb salvage is feasible due to either a) absence of a usable pedal artery target (endovascular or surgical approach), or b) the presence of a pedal artery target with absence of a viable single-segment vein in either lower extremity or either arm that could be used for autogenous vein conduit. 4. Proximally, the Target In-flow Artery at the cross-over point must fall within the recommended vessel diameter ranges for the LimFlow stent graft by visual estimation. 5. Subject is willing and able to sign the informed consent form. 6. Subject is enrolled in an acceptable wound care network and has an adequate support network to ensure that subject is compliant with medication regimen and follow-up study visits. 7. Prior to enrollment (7-day window), women of childbearing potential must have a negative pregnancy test. 8. Primary wound is stable (e.g., not rapidly deteriorating and/or showing signs of healing). 9. Stable glycemic control, HbA1C \< 10% (\<269mg/dL) 10. Subjects requiring dialysis may be included, provided they meet all the following requirements: * On dialysis for \> 6 months * Autologous arteriovenous (AV) fistula or peritoneal access used for hemodialysis * Serum albumin \> 30 g/liter * BMI \> 20
Exclusion criteria
1. Concomitant hepatic insufficiency, thrombophlebitis in the target limb, or non-treatable coagulation disorder within the past 90 days. 2. Active immunodeficiency disorder or currently receiving immunosuppressant therapy for an immunodeficiency disorder. 3. Prior peripheral arterial bypass procedure above or below the knee which would inhibit proximal inflow to the stent graft. 4. Absence of adequate viable tissue in target foot. 5. Life expectancy less than 12 months. 6. Documented myocardial infarction or stroke within previous 90 days. 7. Active infection (e.g., fever, significantly elevated WBC count \>20.0 x 109/L, and/or positive blood culture) at the time of the index procedure that may preclude insertion of a prosthesis or require major amputation (e.g., osteomyelitis proximal to metatarsals). 8. Known or suspected allergies or contraindications to aspirin or P2Y12 inhibitors, heparin, stainless steel, nitinol or contrast agent that cannot be adequately pre-treated. 9. Subject is currently taking anti-coagulants, which in the opinion of the investigator, interferes with the subject's ability to participate in the study (i.e., intermittent interruption of therapy for procedure may compromise subject's safety). 10. Lower extremity vascular disease that may inhibit the procedure and/or jeopardize wound healing (e.g., vasculitis, Buerger's disease, significant edema in the target limb, deep venous thrombus in the target vein, hyperpigmentation, or medial ulceration above the ankle). 11. Significant acute or chronic kidney disease with a serum creatinine of \> 2.5 mg/dl in subjects not undergoing dialysis. 12. Severe heart failure (e.g., NYHA Class IV), which in the opinion of the investigator may compromise subject's ability to safely undergo a percutaneous procedure. 13. Any significant concurrent medical, psychological, or social condition, which may significantly interfere with the subject's optimal participation in the study, in the opinion of the investigator. 14. The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study. 15. Subject is unwilling, unable, or unlikely for cognitive or social reasons to comply with any of the protocol or follow-up requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Amputation Free Survival | 6 Months | Freedom from major (above-ankle) amputation and death (all-cause mortality) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Primary Patency | 30 Days | Absence of occlusion of the endovascular intervention that is maintained without the need for additional or secondary surgical or endovascular procedures |
| Primary Assisted Patency | 30 Days | Absence of occlusion of the endovascular intervention maintained with the use of additional or secondary surgical or endovascular procedures, as long as occlusion of the primary treated site has not occurred |
| Secondary Patency | 30 Days | Absence of occlusion of the endovascular intervention that is maintained with the use of additional or secondary surgical or endovascular procedures after occlusion occurs |
| Limb Salvage | 30 Days | Percentage of subjects with freedom from above-ankle amputation of the index limb |
| Change in Rutherford Classification | 30 Days | A change of one class or greater |
| Technical Success | Intraprocedurally | The successful creation of an arteriovenous fistula in the desired limb location with immediate morphological success |
| Procedural Success | 30 Days | The combination of technical success, and absence of all-cause death, above-ankle amputation or clinically driven major re-intervention of the stent graft |
| Target Wound Healing | 30 Days | Complete healing of the patient's target wound |
| All Wound Healing | 30 Days | Complete healing of the patient's wounds |
| All Wound Area Reduction | 30 Days | Reduction in area of the patient's wounds |
| Freedom from Contrast-Induced Nephropathy | 72 hours | Subjects without acute (within 72 hours after intravenous contrast administration) impairment of renal function, measured as an absolute ≥0.5 mg/dL (44 μmol/L) increase compared to baseline SCr value that results in a value above the upper limit of the normal range. |
| Procedure Time | Intraprocedurally | The time of the first puncture (venous or arterial) to when the last catheter is removed |
| Radiation Exposure | Intraprocedurally | Patient radiation exposure (in milligray) during the procedure |
| Contrast Volume | Intraprocedurally | The total volume of contrast media (in milliliters) given during the procedure |
Countries
United States
Contacts
CONTACTErin Towery
PRINCIPAL_INVESTIGATORDaniel Clair, MD
Vanderbilt University
PRINCIPAL_INVESTIGATORMehdi Shishehbor
University Hospital Cleveland
Outcome results
None listed